Fasenra 30mg PFS (Benralizumab PFS) 30mgx1ml

Fasenra 30mg PFS (Benralizumab) is an injectable prescription medication used for add-on maintenance treatment of severe asthma in adults and adolescents. Store between 2-8°C to maintain potency. Always follow healthcare provider instructions for use.

Strength

30mgx1ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Astrazeneca AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fasenra 30mg PFS is prescribed as an add-on maintenance treatment for patients with severe asthma who have an eosinophilic phenotype. It helps reduce asthma attacks and improves lung function when used regularly. This medication is not a rescue inhaler and does not replace inhaled corticosteroids. It is administered as a subcutaneous injection by a healthcare professional or self-injected after proper training.

Side Effects

After starting Fasenra 30mg PFS, some patients report fewer asthma symptoms and reduced need for oral corticosteroids. Most users experience mild injection-site reactions like redness or swelling. Effects may take several weeks to become noticeable as the medication works gradually to reduce airway inflammation.

Precautions & Warnings

Keep Fasenra 30mg PFS refrigerated between 2-8°C and protect from light. Do not freeze or shake vigorously. Inspect the pre-filled syringe for particles or discoloration before use. Dispose of used syringes in a sharps container. Always inform your healthcare provider about current medications and medical conditions before starting treatment.

Avoid Interactions

Fasenra 30mg PFS has not been shown to interact significantly with common medications like inhaled corticosteroids or bronchodilators. No specific drug interactions have been identified in clinical studies. However, always disclose all medications, including over-the-counter drugs and supplements, to your healthcare provider. Live vaccines should be avoided during treatment unless approved by a doctor.

Frequently Asked Questions

Fasenra 30mg PFS is used as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents.

It is given as a subcutaneous injection, either by a healthcare professional or self-injected after proper training.

No, Fasenra 30mg PFS must be stored refrigerated between 2-8°C and protected from light.

No, it is an add-on treatment and does not replace inhaled corticosteroids or rescue inhalers.

Contact your healthcare provider to discuss rescheduling the dose as soon as possible.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.